Castuner

GHAPPcast

Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)

This is the official podcast of The Gastroenterology & Hepatology Advanced Practice Providers (GHAPP), an association is dedicated to developing educational programs, providing professional advancement services, and assembling resources for—and guided by—advanced practice providers (APPs). Through our peer-to-peer network, we seek to support their integral role in the specialty healthcare community by providing the most relevant and timely information and communication for the treatment of their patients with gastrointestinal (GI) disorders and chronic liver disease (CLD).

Сайт подкаста

Слушайте в своём приложении

Эпизоды

169 эпизодов

  1. FAQ: HCV: Is It Still an Issue? 4:52
  2. Podcast: Keep Calm and Liver On 7:26
  3. Podcast: Behind the Scenes of GHAPP National Planning 14:23
  4. Podcast: AI in GI: Hype, Help, or the Future 8:08
  5. Podcast: What is the GHAPP Peer Network? 7:06
  6. Linerixibat Medication Review 13:10
  7. Podcast: Managing Fatigue and Pruritus in Your Patients With PBC 15:13
  8. Podcast: How to Screen and Diagnose Cholestatic Liver Diseases 20:07
  9. GHAPPcast: Recognizing and Managing Overt Hepatic Encephalopathy 48:00
  10. FAQ: Counseling Patients on Overt Hepatic Encephalopathy 4:52
  11. FAQ: Identifying & Diagnosing Overt Hepatic Encephalopathy 2:23
  12. Subgroup Analysis: Differences in Maintenance Dosing For UC and CD 7:55
  13. Medication Review: Efficacy & Safety of Risankizumab in Patients with Moderate to Severely Active UC 17:14
  14. Med Review: SEQUENCE Trial: Risankizumab vs Ustekinumab in Anti-TNF-Refractory Crohn’s Disease 12:26
  15. FAQ: QUASAR Long Term Extension Interim Analysis 4:34
  16. Medication Review: Guselkumab IV vs SC Formulation 3:25
  17. FAQ: Recognizing OHE Risk in Patients with Chronic Liver Disease 2:30
  18. FAQ: Phase 3 GALAXI 2 & 3: Extraintestinal Manifestations In Moderate to Severe Crohn’s Disease 5:01
  19. Medication Review: Monotherapy vs. Combination Therapy: Relevance in IBD Treatment Strategy 3:08
  20. Medication Review: Stable PK Supporting Continuous Inflammatory Control 6:56
  21. Journal Club: ASTRO Phase 3 Study: Efficacy and Safety of SC Guselkumab 5:41
  22. Journal Club: Benefit–Risk Profile of Upadacitinib in Patient’s With Moderate to Severe UC and CD 23:31
  23. Podcast: How Do You Best Support Patients Getting Started on New MASH Treatments? 18:38
  24. Podcast: Best Practices For Patient Identification 17:03
  25. Podcast: SubQ Solutions: Induction and Maintenance in Moderately to Severely Active CD and UC 23:08
  26. FAQ: Treat Through VS Randomized Withdrawal Design: What's The Difference? 3:35
  27. Medication Review: GALAXI & GRAVITI Clinical Trials & LTE Data 5:41
  28. Podcast: Inflammation Intersection: A Rheum-Gi Dialogue 36:24
  29. Journal Club: Risankizumab Long-Term Efficacy in Crohn’s Disease: FORTIFY Extension Results 7:26
  30. Podcast: Upadacitinib FDA Label Update: What Clinicians Need to Know 15:53
  31. FAQ: Biomarkers: The Non-Invasive Future of HCC Detection 1:56
  32. FAQ: Approved Systemic Therapy in Upadacitinib’s Expanded UC and CD Indications 2:36
  33. FAQ: What Does Clinically Inadvisable Mean in Upadacitinib’s Expanded UC and CD Indications? 3:33
  34. FAQ: How Do You Balance Systemic and Liver Directed Therapies in Patients With MASH? 2:49
  35. FAQ: What is the Relevance of Assessing Alcohol Consumption in Patients With MASH? 5:30
  36. Medication Review: Resmetirom: Thyroid Hormone Receptor-β Agonism in MASH Treatment 4:51
  37. APP Roundtable: Approach To Starting Treatments in Patients With CHB 12:37
  38. APP Roundtable: Navigating Difficult Conversations in CHB 25:10
  39. APP Roundtable: Addressing Co-Morbidities in CHB 19:53
  40. FAQ: What Role Do NITs Play in Risk Stratification & Patient Selection—& Balancing Patient History? 1:35
  41. Journal Club: Review of Focused Recommendations for the Management of MASLD 10:23
  42. Medication Review: Resmetirom: Core Efficacy Data and Patient Selection Considerations 10:38
  43. FAQ: What Are The Functional And Prognostic Differences Between Fibrosis F3 And F4 Patients? 4:13
  44. The Conversation That Matters: Talking to Patients About Obesity and IMIDs 15:02
  45. From Insight to Action: Practical Strategies to Improve Outcomes in Patients with Obesity and IMIDs 15:59
  46. GHAPPcast: Women of Childbearing Age With IBD 24:17
  47. The Hidden Costs: Obesity’s Role in Suboptimal Outcomes and Healthcare Burden in IMIDs 18:10
  48. FAQ: How Do You Explain Remission To A Patient? 5:41
  49. GHAPPcast: Mental and Sexual Health Concerns & How To Address Them For Your IBD Patient 9:40
  50. Obesity and IMIDs: Unpacking the Epidemic and Its Far-Reaching Impacts 18:34